Stock APLT APPLIED THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.28 USD +1.18% Intraday chart for Applied Therapeutics, Inc. -2.28% +27.76%
Apr. 15 Applied Therapeutics, Inc. Announces Management Changes CI
Mar. 28 Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review DJ

Evolution of the average Target Price on Applied Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

85491a534.6HUf0gEP1ZVS2uPfDv8UO_31COLhhcfWUMvqGQXsoqQ.qgcvlXc3kuE0ic6yRI18f5yTZ4HT4pKGYL2PU0qu-PCSO16gSV7s5wqvrg~b04f9d4513196925d021449dc9100240

Analyst Recommendations on Applied Therapeutics, Inc.

RBC Initiates Applied Therapeutics at Outperform, Speculative Risk With $12 Price Target, Sees Lead Drug Govorestat 'Well-Positioned for Success' MT
UBS Adjusts Applied Therapeutics Price Target to $13 From $12, Maintains Buy Rating MT
UBS Adjusts Applied Therapeutics Price Target to $12 From $4, Maintains Buy Rating MT
Leerink Partners Initiates Applied Therapeutics at Outperform Rating $12 Price Target MT
S&P 500, Nasdaq climb as fresh data boosts rate-cut bets again RE
US job data raises doubts about the Fed's next moves Our Logo
Waning Rate Cut Hopes, Employment Situation Report Push Down Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT
Baird Adjusts Applied Therapeutics Price Target to $14 From $18, Maintains Outperform Rating MT
Citigroup Adjusts Applied Therapeutics Price Target to $5 From $23, Maintains Buy Rating MT
Citigroup Cuts Price Target on Applied Therapeutics to $23 From $29, Keeps Buy Rating MT
Citigroup Adjusts Applied Therapeutics' Price Target to $29 from $30, Keeps Buy Rating MT
Truist Securities Adjusts Price Target on Applied Therapeutics to $6 From $85, Reiterates Buy Rating MT
Barclays Adjusts Price Target on Applied Therapeutics to $2.50 From $7, Keeps Equalweight Rating MT
Citigroup Adjusts Applied Therapeutics' Price Target to $30 From $38, Reiterates Buy Rating MT
Goldman Sachs Adjusts Price Target on Applied Therapeutics to $3 From $10, Reiterates Sell Rating MT
Barclays Downgrades Applied Therapeutics to Equalweight From Overweight, Slashes Price Target to $7 From $44 MT
APPLIED THERAPEUTICS : Goldman Sachs Cuts Applied Therapeutics to Sell From Neutral, Price Target to $10 From $16 MT
APPLIED THERAPEUTICS : UBS Adjusts Price Target on Applied Therapeutics to $48 From $67 on Adjusted AT-001, AT-007 Timelines; Buy Rating Kept MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.28 USD
Average target price
11.6 USD
Spread / Average Target
+171.03%
High Price Target
14 USD
Spread / Highest target
+227.10%
Low Price Target
7 USD
Spread / Lowest Target
+63.55%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Applied Therapeutics, Inc.

RBC Capital Markets
UBS
Leerink Partners
Baird
Citigroup
Truist Securities
Barclays
Goldman Sachs

Ratings for Applied Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. APLT Stock
  4. Consensus Applied Therapeutics, Inc.